Kornimate/medical-research-clean huggingface dataset:
zoledronic acid in decrease the lung metastatic rate of osteosarcoma

Conditions: Lung Metastases; Tumor Necrosis

Summary: zoledronic acid is an adjuvant treatment for primary osteosarcoma. zoledronic acid has been widely used in the treatment of metastatic bone tumors. in addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. we hope that it can reduce tumor recurrence and lung metastasis through this study.


Eligibility criteria:
inclusion criteria: * patients with osteosarcoma who were diagnosed with initial pathology and pathology were excluded from lung metastasis or other metastatic lesions by ct and total body emission-computed tomography, and patients with standard chemotherapy were evaluated. exclusion criteria: * pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine clearance \<70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable for bisphosphonate treatment after evaluation, have been found. with diseases that still require hormone therapy, abnormal blood system, heart disease
toward high fidelity adaptive radiotherapy in the thorax

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: daily adaptive radiotherapy with individualized planning margins for thoracic and pelvic cancer patients will increase the potential of reducing dose to oars, thereby reducing treatment-related toxicities and ultimately providing these patients with a better quality of life. thus, the overarching objective of this work is to develop a cbct-guided adaptive workflow and to measure the benefits to patients of the adaptive treatment paradigm utilizing patient reported outcomes in a first-of-kind study.

1. to individualize the planning margins used for treatment, we will assess the impact of the different uncertainties on patient-specific planning margins. we determine the dosimetric uncertainties for patients during planning and delivery through the daily adaptive process. in so doing, we will determine the relationship between the dose distributions and the associated treatment outcomes. 2. to perform retrospective clinical studies using patient data, we determine the relationship between dosimetry from plans developed using the optimized patient-specific margins (plans from (1) that are robust to uncertainties) and retrospective, clinical outcomes. this data will be used to inform daily adaptation and plan quality criteria for a prospective clinical protocol. 3. to develop (with our clinical collaborators) a first-of-kind study to measure the efficacy of daily adaptive treatment with individualized planning margins, using clinical and quality of life (patient reported) outcomes, and to compare these against the conventional treatment approach, where a single treatment plan with population-based treatment margins is utilized for all treatment fractions.

Eligibility criteria:
inclusion criteria: * histologically confirmed non-small cell lung cancer patients * locally advanced
a small-group intervention to reduce hiv sexual transmission risk behavior among hiv-positive men who have sex with men

Conditions: Risk Behavior

Summary: gay poz sex (gps) is an hiv prevention and sexual health promotion program for hiv-positive gay and bisexual men, which takes place in a group counselling format. all participants provided written informed consent at the outset of the study. eligible participants filled out a 1-hour computer-assisted self-interview questionnaire. subsequently, participants attended seven 2-hour group sessions, led by 2 peer facilitators, who were hiv-positive gay men, in groups of 5-8 men. immediately and 3 months following the completion of the gps program, participants were scheduled to attend a 1-hour session to complete the same questionnaire package. participants received an honorarium and a list of community resources, including mental health or substance use counseling services, at the end of each assessment. participants also participated in a program evaluation interview at the 3-month follow-up assessment.


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in the study, participants had to: 1. identify as male, 2. report engaging in condomless anal sex with another male during the past 3 months, 3. self-report an hiv-positive status, 4. be over the age of 18 years old, and 5. be able to speak and read in english. exclusion criteria: * self-reported female gender, * no condomless anal sex with another male during past 3 months, * hiv-negative
an ecological analysis of nontuberculous mycobacteria in the geneva area (2015-2020)

Conditions: Ecology of Nontubercuous Mycobacteria; Geneva Area

Summary: prevalence of ntm diseases has been increasing regularly over the past 30 years in industrialized countries although ntm are identified worldwide, there are important geographical disparities as to the relative prevalence of ntm species there are no data covering the ecology of ntm in switzerland. because of the progressive increase in ntm clinical cases in area geneva(as noted in other industrialized countries), reporting the specific ntm distribution is important and relevant. in this study, the investigators aimed to: 1/ describe the relative prevalence of ntm species in clinical samples analyzed in the geneva area, covering ca 500'000 inhabitants over a 5-year period; 2/ determine how many culture positive patients were treated; and 3/ specify the clinical sites involved.

this study was performed in the geneva university hospitals (hug), a 2008-bed complex providing care for a population of ca. 500'000 inhabitants. all clinical samples sent for microbiological analysis within hug are treated by the bacteriology laboratory of geneva university hospitals. an online database is kept up-to-date and includes all samples processed by the laboratory. the investigators performed a comprehensive analysis of all clinical samples included in this database over a 5-year period (2015-2020). this report focuses only on positive results for nontuberculous mycobacteria (ntm).the following items were recorded: age, gender, bmi whenever available, site of infection (when pulmonary: description of main radiological abnormalities), presence and type of immunosuppression, relevant pulmonary and non-pulmonary comorbidities, results of microscopy, and ntm species identified. the investigators also recorded whether the patient was treated for the identified ntm or not and if a susceptibility profile had been determined (this is not routinely performed and must be requested by the clinician). the study protocol was approved by their local ethics committee

Eligibility criteria:
inclusion criteria - patients with positive clinical samples for nontuberculous mycobacteria (ntm) exclusion criteria - none
safety study of anti-asthma agent bmec-1217b

Conditions: Asthma

Summary: bmec-1217b is an abbreviated version of an old chinese formulation. the ratio of each component was adopted by the sponsor following the observation that bmec-1217b prepared from this ratio resulted in best pharmacological profile and in vitro bioactivities. bmec-1217b was studied for the pharmacological activity on the release of cysteinyl leukotrienes, il-4 and tnf-alpha in vitro and the airway hyperreactivity. the result indicated that bmec-1217b can inhibit the synthesis of several key pro-inflammatory mediators involved in the pathophysiology of allergic asthma and can also improve lung function in a mouse model of allergic asthma. the purpose of this study is to evaluate the safety and tolerability of increasing dose of bmec-1217b when administered orally in healthy volunteers.


Eligibility criteria:
inclusion criteria: 1. nonsmoking healthy adults between 20 and 40 years old. 2. determined to be in good health based on medical history, clinical laboratory test values within normal range. body weight within 20% of the ideal body weight \[(height - 80) x 0.7\]. 3. no recent history of drug or alcohol abuse within one year prior to study enrollment 4. signed informed consent form. exclusion criteria: 1. has any condition that interferes with the ability of the subject to comply with the requirements of the study. 2. has known allergy to the study drug. 3. has an acute illness or surgery within 28 days prior to study enrollment 4. has participated in other investigational trials within 28 days prior to study enrollment. 5. has taken prescription medication and/or over-the-counter medication\*4 and/or botanical medications within 28 days prior to study enrollment. 6. has alcohol and caffeine consumption within 24 hours prior to the administration of study drug. 7. has evidence of significant renal, cardiovascular, hepatic, hematopoetic, neurological, pulmonary or gastrointestinal pathology, or any other medical reason or disease that might interfere with the study objectives, as determined by the investigator. 8. has donation or receive of more than 450 ml of blood within 28 days prior to the study enrollment. 9. female subjects of child bearing potential who are pregnant, nursing, do not agree to practice effective birth control during the time period from 14 days before administration of study drug to 28 days after administration of study drug, or with irregular or abnormal menstruation. 10. clinically significant deviation from normal physical examination findings that, in the principal investigator's judgment, may interfere with the study evaluation or affect subject safety. 11. test positive for hiv, hbv or hcv 12. test results indicate liver function failure 13. has been diagnosed with diabetes mellitus
effects of dexamethasone on common bile duct cannulation time

Conditions: Common Bile Duct Diseases; Common Bile Duct Calculi; Common Bile Duct Stricture; Common Bile Duct Neoplasms; Common Bile Duct Dilatation

Summary: the main aim of this clinical trial is to evaluate the effects of dexamethasone on common bile duct cannulation time during endoscopic retrograde cholangiopancreatography (ercp) in patients with biliary pathologies. the study will also study the effects of dexamethasone on total procedure time and total fluoroscopy time during ercp. participants will be divided into two groups, treatment group and placebo group. patients in treatment group will receive dexamethasone and those in placebo group will be given normal saline before undergoing ercp. the results in both groups will be compared to determine the effects of dexamethasone.


Eligibility criteria:
inclusion criteria: * age: 18 years or above * both genders, male and female patients exclusion criteria: * age younger than 18 years or below * pregnant females * pre existing stent in cbd or pancreatic duct * previous history of ercp * patients with billroth ii surgery * anatomical abnormalities * lack of competence in patients * roux en y gastric bypass * patients with contra indications for steroids like dm

Keywords: ercp, steroids, dexamethasone, cbd cannulation time
prospective stratification of infectious risks in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this monocentric study is to identify factors that increase the susceptibility for infections and establish a questionnaire-based infection score that allows a prospective stratification for infectious risks in patients with multiple sclerosis (ms) (inrims-study). the study will utilize a validated, ms-adapted questionnaire and infection diary from the airway infection susceptibility (awis) study in a regularly followed, prospective cohort of ms patients. it is a nested project of the prospective observational swiss ms cohort (smsc) and summit (serially unified multicenter multiple sclerosis investigation) studies.


Eligibility criteria:
inclusion criteria: * signed informed consent form (icf) for the inrims-study and swiss ms cohort (smsc) and/or serially unified multicenter multiple sclerosis investigation (summit) study exclusion criteria: * not able to sufficiently understand the patient information and questionnaire (german language) * ms patients with long-term antibiotic prophylaxis * ms patients with known primary immunodeficiency, under chemotherapy due to any malignancy or hiv infection.

Keywords: secondary immunodeficiencies disease-modifying treatments (dmt) immunosuppressive therapy serious infection respiratory tract infections (rti) urinary tract infections infection diary swiss ms cohort (smsc) summit (serially unified multicenter multiple sclerosis investigation) studies
intermediate-size patient populations expanded access to treatment for sarcopenic obesity

Conditions: Sarcopenia; Obesity and Obesity-related Medical Conditions

Summary: the expanded access is designed for patients requesting the treatment, and whose medical condition may benefit from treatment, but are unable to participate in any other imm01-stem clinical trial in their physician's opinion for reasons that include: (1) they do not meet enrollment criteria, or (2) they cannot perform the assessment of outcomes, or (3) the trial site is not geographically accessible.


Eligibility criteria:
inclusion criteria: 1. sex: male or post-menopausal female (as defined by the absence of a period for at least 12 consecutive months) 2. race/nationality: all races and ethnicities accepted for which there are validated reference values for obesity and sarcopenia diagnostic criteria 3. disease characteristics: to be eligible, the participant must meet one criterion for obesity and at least one criterion for sarcopenia, as defined below: obesity: 1. abdominal obesity defined by a waist circumference ≥ 40 inches (102 cm) for men, ≥ 35 inches (88 cm) for women (american heart association) 2. abdominal obesity as a waist-to-hip ratio of at least 0.90 in men and 0.85 or more for 3. no obesity, normal bmi women (world health organization) sarcopenia: i) grip strength: \< 16 kg (women), \< 27 kg (men) in the dominant hand, or, ii) gait speed \< 0.8 m/s (men and women) iii) clinical evidence of sarcopenia alternative to grips strength and gait speed measurements, as judged by the physician exclusion criteria: 1. qualifying individuals by the current enrollment criteria that are in a 50-mile geographical radius of any imm01-stem clinical trial site or a potential clinical site. 2. inability to sign an informed consent 3. concomitant investigational drugs and treatments 4. concomitant medication included in the table 1. 5. current malignancy or recent malignancy in complete remission less than 3 years 6. bmi \< 20 7. major surgical procedures in the past 30 days. 8. cognitive impairment, alzheimer disease, 9. progressive autoimmune disorders including rheumatoid arthritis, muscular dystrophy, multiple sclerosis, systemic sclerosis, inclusion body myositis, idiopathic inflammatory myopathy, and similar conditions.
purified cd34+ hematopoietic stem cell transplantation from alternate donors for patients with severe aplastic anemia

Conditions: Aplastic Anemia

Summary: this study is for patients with severe aplastic anemia (saa). a stem cell transplant from a genetically matched sibling donor can help or cure this disease in 85 to 100 percent of patients. stem cells are immature blood cells that grow to become red blood cells, white blood cells or platelets. a genetic "match" means a brother or sister has same immune type (hla type) as the patient. unfortunately, few patients have a matched sibling donor. the chance of negative outcomes is much higher with other types of donors. this study will test the success of a new approach to stem cell transplant for saa. patients in this study will receive drugs and radiation treatment to destroy their diseased bone marrow and to prepare them for stem cell transplant. bone marrow is the tissue inside the bones where stem cells are made.stem cells will be harvested from the blood or bone marrow of genetically matched unrelated donors or partially matched family donors. the stem cells will be filtered using a new device that is currently under study. the patients will receive large doses of the filtered stem cells (stem cell graft). researchers want to find out how the study treatment affects patients, the disease, and the chances for survival.


Eligibility criteria:
inclusion criteria: * age \< 21 years * diagnosis of severe aplastic anemia. (as defined by at least 2 of the following: anc \< 500/μl, platelet count \< 20,000/μl, and a reticulocyte count \< 1% after correction for the hematocrit. in addition, the diagnostic bone marrow biopsy must contain less than 25% of the normal cellularity). * patient must have failed one or more courses of immunosuppressive therapy that included atg. as immunosuppression may take up to 6 months to demonstrate a response, patients must have been observed to have failed immunosuppression for a minimum of six months. * absence of suitable hla-matched sibling donor. * negative serum pregnancy test for females with child bearing potential. * patient/parent/guardian is able to provide informed consent. exclusion criteria: * patients with a life expectancy \< 6 weeks. * patients with severe renal disease (creatinine clearance \< 40cc/min/1.73m2) * patients with pre-existing severe restrictive pulmonary disease (fvc \<40% of predicted)

Keywords: aplastic anemia
study of the safety and efficacy of dichloroacetate (dca) in glioblastoma and other recurrent brain tumors

Conditions: Brain Tumor; Glioblastoma

Summary: the purpose of this study is to evaluate the safety and tolerability of oral dichloroacetate (dca) in the treatment of recurrent malignant brain tumors (rmbts). rmbts are defined as either: 1) malignant tumors, originating in the brain, that have recurred at least once or 2) malignant tumors originating elsewhere in the body that have spread to the brain at least once. otherwise, there are no limitations to the number of prior recurrences. there are no limitations to the number or types of prior therapies.

malignant brain tumors are defined as any world health organization grade iii-iv glioma and any solid tumor metastasis (spread) to the brain. recurrent malignant brain tumors (rmbts) are defined as either: 1) malignant tumors, originating in the brain, that have recurred at least once or 2) malignant tumors originating elsewhere in the body that have spread to the brain at least once. they share an increasing incidence, clinical and radiographic characteristics, lack of effective therapies, tendency to recur, and poor outcome. importantly, recurrent malignant brain tumor's shared characteristics may be usefully exploited by an emerging class of biologic agents called metabolic modulators of which dichloroacetate (dca) is the drug in the class most thoroughly investigated clinically. dca's mechanism of action and tolerability have been extensively demonstrated in the treatment of chronic metabolic disorders. furthermore, the preciseness of dca's mechanism of action appears to target abnormal tumor cell metabolism.

Eligibility criteria:
inclusion criteria: * subject must be able to consent for self. subject must have either: 1. a brain metastasis or 2. a who iii-iv glioma that has recurred at least once. females of child bearing age must have (-) pregnancy test. * females of child bearing age must use birth control while in study. * adequate organ function as determined by laboratory testing. * absence of peripheral neuropathy of moderate or greater severity (physician determined). * greater than 4 weeks time from previous anti-neoplastic (anti-cancer) therapy. * subject must have a karnofsky performance status (kps) of greater than or equal to 60. * subject must have an ecog performance status of less than or equal to 2. * there are no limitations to the number of prior recurrences. * there are no limitations to the number or types of prior therapies. exclusion criteria: * medical contraindication for magnetic resonance imaging (mri)testing.

Keywords: brain tumors, glioblastoma and dca brain tumor,glioblastoma recurrent
prospective research rare kidney stones (prorks)

Conditions: Hyperoxaluria; Cystinuria; Dent Disease; Lowe Syndrome; Adenine Phosphoribosyltransferase Deficiency

Summary: the purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (ckd), primary hyperoxaluria (ph), cystinuria, dent disease and adenine phosphoribosyltransferase deficiency (aprtd) and acquired enteric hyperoxaluria (eh). the investigator will measure blood and urinary markers of inflammation and determine relationship to the disease course. cross-comparisons among the disorders will allow us to better evaluate mechanisms of renal dysfunction in these disorders.

severe, hereditary forms of nephrolithiasis cause marked excretion of insoluble minerals important in stone formation, including primary hyperoxaluria, cystinuria, dent disease, and adenine phosphoribosyltransferase deficiency (aprtd). patients with these disorders experience recurring stones from childhood and are at high risk for chronic kidney disease caused by crystal nephropathy. enteric hyperoxaluria is an acquired disease characterized by hyperoxaluria and calcium oxalate crystal nephropathy associated with chronic kidney disease, and in that respect similar to the inherited stone diseases. the investigators will collect longitudinal data of individual patients in order to provide clues about potentially modifiable factors that influence disease severity and identify factors leading to kidney injury. the investigator will measure blood and urinary markers of inflammation and determine relationship to the disease course. cross-comparisons among the disorders will allow to better evaluate mechanisms of renal dysfunction in these diseases.

Eligibility criteria:
inclusion criteria: 1. diagnosis of primary hyperoxaluria 2. diagnosis of enteric hyperoxaluria 3. diagnosis of dent disease 4. diagnosis of cystinuria 5. diagnosis of adenine phosphoribosyltransferase deficiency (aprtd) 6. diagnosis of lowe syndrome 7. diagnosis of dent disease carrier exclusion criteria: 1. prior renal failure 2. history of liver and/or kidney transplant.

Keywords: primary hyperoxaluria dent disease enteric hyperoxaluria cystinuria lowe syndrome adenine phosphoribosyltransferase deficiency ph aprtd aprt hyperoxaluria oxalate oxalosis ph type 1 ph type 2 ph type 3 dents dent dent 1 dent 2 aprt deficiency
parent/nurse controlled analgesia in the neonatal intensive care unit

Conditions: Abdominal Surgery; Thoracic Surgery

Summary: the aim of this study is to examine the safety and effectiveness of 2 morphine delivery systems for post-surgical neonates. the investigators hypothesize that this study will be feasible to conduct, and that neonates receiving morphine via a parent/nurse controlled analgesia pump will receive less morphine and experience fewer side effects than neonates receiving morphine via continuous opioid infusion.


Eligibility criteria:
inclusion criteria: * surgery location: * abdominal or thoracic * first surgery only age: * born ≥ 34-44 weeks post-menstrual age * weight: weight at birth or current weight ≥2 kg intubated or extubated prior opioid exposure: * \< 2 days of continuous exposure * if history of \> 2 day continuous exposure, must be off continuous drip for a week * intermittent exposure ≤ 2 days prior to surgery neonates exposed to chronic opioids in utero \*in utero exposure to selective seretonin reuptake inhibitors and illicit drugs will be screened for and annotated. at least 1 parent is english-speaking exclusion criteria: * surgery type: * cardiac, patent ductus arteriosus ligation; omphalocele (if intubated pre-operatively) diagnoses: • necrotizing enterocolitis; diaphragmatic hernia (unless thoracoscopically repaired); chemically or physiologically paralyzed receiving vasopressors receiving acetaminophen or a benzodiazepine (lorazepam or midazolam) ≤ 24 h before surgery patients with any of the following: epidural; oscillating ventilator

Keywords: neonatal intensive care unit neonate pain morphine parent/nurse controlled analgesia